Compare Novavax Inc (NVAX) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ON Holding AG — how do they compare? Novavax Inc trades at $12.69 (market cap $1.82B), while ON Holding AG trades at $35.07 (market cap $11.38B). The key difference: ON Holding AG is far larger — about 6.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and ON Holding AG for 22 Days on average.
| NVAX | ONON | |
|---|---|---|
Market Cap | $1.82B | $11.38B |
Volume | 6,198,505 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $50.63 |
52-Week Low | $6.22 | $26.76 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $1.39B | $10.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
ONON stock trades at $35.09, up 5.63% with strong bullish momentum. The company demonstrates robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 versus $0.42 expected. Recent investor day announcements of a $1 billion buyback program and ambitious 2029 targets have fueled positive sentiment. Technical indicators show bullish moving averages but overbought RSI conditions.
Outlook remains positive with analyst consensus at $42.26 target (20% upside) and 74% buy ratings. Key opportunities include premium store expansion and new sports categories, while risks involve execution on growth targets and competitive pressures in athletic footwear. The stock's current valuation at 24x P/E reflects growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
